Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 May 4;20(8):1089–1103. doi: 10.1016/j.bbmt.2014.04.028

Figure 1. Anti-CD20 mAb Prevents Induction of Chronic GVHD in BALB/c Recipients Given MHC-matched Donor DBA/2 Bone Marrow Transplants.

Figure 1

Lethally irradiated BALB/c recipients were transplanted with spleen cells (75×106) and BM cells (2.5 ×106) from DBA/2 donors and injected i.v. with either rat IgG or anti-CD20 mAb (40 mg/Kg) the following day. Control recipients were given BM cells alone. Recipients were monitored for clinical GVHD, including hair loss, proteinuria and survival († indicates death of all recipients in a group). (A–C) Percentage of recipients without (A) proteinuria, (B) clinical cutaneous GVHD score, and (C) percentage of survival. Each group contained 20 recipients combined from five replicate experiments. (D) Twenty-five and one hundred days after HCT, recipients thymuses were measured for percentage of CD4+CD8+ thymocytes and a representative pattern is shown of 4 replicate experiments.